(R) -Ketorolac

(R) -Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R) -Ketorolac inhibits GTPase. (R) -Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R) -Ketorolac ameliorates cancer-associated cachexia[1][2][3].

Product Specifications

CAS Number

[66635-93-6]

Product Name Alternative

(+) -Ketorolac

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/r-ketorolac.html

Purity

99.65

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=CC=CC=C1)C2=CC=C3N2CC[C@H]3C(O)=O

Molecular Formula

C15H13NO3

Molecular Weight

255.27

Precautions

H315, H319, H335

References & Citations

[1]Handley DA, et al. Preclinical enantioselective pharmacology of (R) - and (S) - ketorolac. J Clin Pharmacol. 1998 Feb;38 (2S) :25S-35S.|[2]Guo Y, Kenney SR, Muller CY, et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015;14 (10) :2215-2227. |[3]Chrysostomou SE, et al. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2024 Apr;15 (2) :562-574.